Alpine Immune Sciences, Inc.
ALPNNASDAQHealthcare
$64.97
+$0.01(+0.02%)
Market Cap$4.5B
P/E Ratio—
52W High$65.0
52W Low$8.33
Alpine Immune Sciences, Inc. (ALPN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ALPN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2024Report Date: May 9, 2024EPS Actual
-$0.28
Est. -$0.43 · +34.9%
Revenue
$0.01B
Est. $0.00B · +101.5%
Fiscal Period
Q2 FY2024
FY ends December
Report Date
May 9, 2024
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 5-Quarter EPS Beat Streak
ALPN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q2 FY2024 | May 9, 2024 | -$0.43 | -$0.28 | +34.9% | $0.01B | $0.00B | +101.5% |
| ▲ Q1 FY2024 | Mar 18, 2024 | -$0.34 | $0.12 | +135.3% | $0.03B | $0.01B | +239.0% |
| ▲ Q4 FY2023 | Nov 14, 2023 | -$0.35 | -$0.24 | +31.4% | $0.01B | $0.01B | -0.9% |
| ▲ Q3 FY2023 | Aug 14, 2023 | -$0.38 | -$0.27 | +28.9% | $0.01B | $0.01B | -2.9% |
| ▲ Q2 FY2023 | May 11, 2023 | -$0.37 | -$0.28 | +24.3% | $0.01B | $0.01B | +9.2% |
| ▼ Q1 FY2023 | Mar 23, 2023 | -$0.27 | -$0.41 | -51.9% | $0.00B | $0.01B | -74.7% |
| ▼ Q4 FY2022 | Nov 14, 2022 | -$0.10 | -$0.42 | -320.0% | $0.01B | $0.02B | -55.2% |
| ▼ Q3 FY2022 | Aug 11, 2022 | -$0.39 | -$0.60 | -53.9% | $0.01B | $0.01B | -47.3% |
Q2 FY2024
May 9, 2024Beat
EPS Actual
-$0.28
EPS Est.
-$0.43
EPS Surpr.
+34.9%
Revenue
$0.01B
Q1 FY2024
Mar 18, 2024Beat
EPS Actual
$0.12
EPS Est.
-$0.34
EPS Surpr.
+135.3%
Revenue
$0.03B
Q4 FY2023
Nov 14, 2023Beat
EPS Actual
-$0.24
EPS Est.
-$0.35
EPS Surpr.
+31.4%
Revenue
$0.01B
Q3 FY2023
Aug 14, 2023Beat
EPS Actual
-$0.27
EPS Est.
-$0.38
EPS Surpr.
+28.9%
Revenue
$0.01B
Q2 FY2023
May 11, 2023Beat
EPS Actual
-$0.28
EPS Est.
-$0.37
EPS Surpr.
+24.3%
Revenue
$0.01B
Q1 FY2023
Mar 23, 2023Miss
EPS Actual
-$0.41
EPS Est.
-$0.27
EPS Surpr.
-51.9%
Revenue
$0.00B
Q4 FY2022
Nov 14, 2022Miss
EPS Actual
-$0.42
EPS Est.
-$0.10
EPS Surpr.
-320.0%
Revenue
$0.01B
Q3 FY2022
Aug 11, 2022Miss
EPS Actual
-$0.60
EPS Est.
-$0.39
EPS Surpr.
-53.9%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-0.47 | $-0.47 | $-0.47 | 1 |
| Q3 FY2025 | $-0.46 | $-0.46 | $-0.46 | 1 |
| Q2 FY2025 | $-0.48 | $-0.48 | $-0.48 | 1 |
| Q1 FY2025 | $-0.47 | $-0.47 | $-0.47 | 1 |
| Q4 FY2024 | $-0.40 | $-0.40 | $-0.40 | 1 |
| Q3 FY2024 | $-0.50 | $-0.44 | $-0.31 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2024 | May 9, 2024 | +34.9% | $64.70 | $64.82 | +0.19% |
| ▲ Q1 FY2024 | Mar 18, 2024 | +135.3% | $36.38 | $35.47 | -2.50% |
| ▲ Q4 FY2023 | Nov 14, 2023 | +31.4% | $11.56 | $11.96 | +3.46% |
| ▲ Q3 FY2023 | Aug 14, 2023 | +28.9% | $13.58 | $13.25 | -2.43% |
| ▲ Q2 FY2023 | May 11, 2023 | +24.3% | $7.87 | $7.78 | -1.14% |
| ▼ Q1 FY2023 | Mar 23, 2023 | -51.9% | $7.91 | $8.12 | +2.65% |
| ▼ Q4 FY2022 | Nov 14, 2022 | -320.0% | $5.77 | $5.74 | -0.52% |
| ▼ Q3 FY2022 | Aug 11, 2022 | -53.9% | $8.80 | $8.58 | -2.50% |
Q2 FY2024+0.19%
Report Date
May 9, 2024
EPS Beat/Miss
+34.9%
Price Before
$64.70
Price After
$64.82
Q1 FY2024-2.50%
Report Date
Mar 18, 2024
EPS Beat/Miss
+135.3%
Price Before
$36.38
Price After
$35.47
Q4 FY2023+3.46%
Report Date
Nov 14, 2023
EPS Beat/Miss
+31.4%
Price Before
$11.56
Price After
$11.96
Q3 FY2023-2.43%
Report Date
Aug 14, 2023
EPS Beat/Miss
+28.9%
Price Before
$13.58
Price After
$13.25
Q2 FY2023-1.14%
Report Date
May 11, 2023
EPS Beat/Miss
+24.3%
Price Before
$7.87
Price After
$7.78
Q1 FY2023+2.65%
Report Date
Mar 23, 2023
EPS Beat/Miss
-51.9%
Price Before
$7.91
Price After
$8.12
Q4 FY2022-0.52%
Report Date
Nov 14, 2022
EPS Beat/Miss
-320.0%
Price Before
$5.77
Price After
$5.74
Q3 FY2022-2.50%
Report Date
Aug 11, 2022
EPS Beat/Miss
-53.9%
Price Before
$8.80
Price After
$8.58
Avg Beat Reaction-0.48%
Avg Miss Reaction-0.12%
Beat Rate5 / 8 quarters
Largest Move+3.46% (Q4 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ALPN ends December
Alpine Immune Sciences, Inc. (ALPN) most recently reported earnings on May 9, 2024 for Q2 FY2024, posting EPS of $-0.28 — beating the analyst consensus of $-0.43 by +34.9%. ALPN has beaten EPS estimates for 5 consecutive quarters. The next ALPN earnings date is expected around September 1, 2026.
Each quarter, investors track ALPN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ALPN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ALPN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ALPN earnings · 5 questionsAlpine Immune Sciences, Inc.'s next earnings report is expected around September 1, 2026. ALPN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ALPN historically reports after market close (AMC).
ALPN earnings datewhen is ALPN earningsALPN next earnings datewhen does ALPN report earningsALPN earnings calendar
▸ Source: FMP · Alpine Immune Sciences, Inc. SEC filings · US GAAP · Alpine Immune Sciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026